查詢結果分析
來源資料
相關文獻
- Effect of Oral L-Carnitine Supplementation on the Nutritional Status and Muscle Strength of Patients with Chronic Peritoneal Dialysis
- 青少年體操選手飲食及生理狀況之探討
- Subjective Global Assessment Is a Nutritional Status Marker for Chronic Peritoneal Dialysis Patients
- 血液透析中心患者之營養評估
- 取卵時間與小鼠及家兔卵母細胞第一極體(PB1)形態之完整性和染色體之相對位置之關係
- 臺中地區早產兒與足月兒出生時抗氧化營養狀況之比較
- Nutrition and Health Survey in Taiwan (NAHSIT) 1993-1996: Dietary Hutrient Intakes Assessed by 24-Hour Recall
- The Folate Status in Taiwanese Population from the NAHSIT 1993-1996
- 壞死後肝硬化病患的營養評估
- Analysis of Anthropometric Growth Trends and Prevalence of Abnormal Body Status in Tainan Elementary-school Children
頁籤選單縮合
題 名 | Effect of Oral L-Carnitine Supplementation on the Nutritional Status and Muscle Strength of Patients with Chronic Peritoneal Dialysis=口服補充左旋肉鹼對慢性腹膜透析病人營養狀況及肌肉強度的影響 |
---|---|
作 者 | 吳紅蓮; 曾進忠; 吳安邦; 王明誠; | 書刊名 | 臺灣營養學會雜誌 |
卷 期 | 36:1 2011.03[民100.03] |
頁 次 | 頁19-26 |
分類號 | 415.816 |
關鍵詞 | 左旋肉鹼; 體位; 肌肉強度; 營養狀況; 慢性腹膜透析; L-carnitine; Anthropometry; Muscle strength; Nutritional status; Chronic peritoneal dialysis; |
語 文 | 英文(English) |
中文摘要 | 肌肉無力、瘦肌肉流失、及高血脂症在透析病人十分普遍。我們前瞻性的評估口服補充左旋肉鹼(L-carnitine)對慢性腹膜透析病人營養狀況及肌肉強度的影響。採用介入與追蹤的研究。材料與方法:參與研究的病人來自國立成功大學附設醫院已接受腹膜透析的病人有44位,其中19位為A組,每日給予口服補充左旋肉鹼600毫克,即實驗組,另外25位為B組,不給口服左旋肉鹼,即控制組,研究為期6個月,我們在研究前、開始研究後第三個月、結束後評估病人的體位、肌肉強度、血清白蛋白及血脂質。結果:A組在口服補充左旋肉鹼後的第三個月與第六個月的體位、肌肉強度、血清白蛋白及血脂質與研究前皆無顯著的差異。A組與B組在同一個時問的評估比較也無統計上顯著性的差異。但在A組,我們發現口服補充左旋肉鹼後六個月會使研究前三頭肌皮層厚度(triceps skin-fold thickness; TSF)較低的病人其三頭肌皮層厚度顯著的增加。總結:我們發現每日口服補充左旋肉鹼600毫克,無法明顯改善慢性腹膜透析病人的營養狀況及肌肉強度與血脂質,這個可能的原因是給予的口服劑量較低且時間較短。然而口服低劑量的左旋肉鹼可能對原本三頭肌皮層厚度較低的中劉生腹膜透析病人比較有改善的空間及顯示其效果。 |
英文摘要 | Muscle weakness, muscle mass loss, and hyperlipidemia are common complaints in dialysis patients. We prospectively evaluated the effects of oral L-carnitine supplementation on the nutritional status, anthropometrics, muscle strength, and lipid profiles in patients receiving chronic peritoneal dialysis (CPD). This was a interventional and follow-up study. Forty-four CPD patients from National Cheng Kung University Hospital were enrolled. Nineteen patients (group A were treated with 600 mg/day L-carnitine orally (one table qid), and 26 patients (group B) who did not receive L-carnitine served as the control group. The duration of the study was 6 months. We evaluated anthropometrics, muscle strength, and serum albumin and lipid profiles at the start, in the third month, and at the end of the study. After treatment with L-carnitine, there were no significant changes in any parameters in the third month and at the end of study for patients in group A. There were no significant differences between the two groups in the same month. L-Carnitine treatment increased the triceps skin-fold (TSF) thickness only in lower-TSF patients in group A. We found that treatment with 600 mg/day L-carnitine orally did not improve the nutritional status of CPD patients. This may have been a consequence of the relatively small dosage via the oral route and short duration of treatment. However, a low dosage of L-carnitine might be beneficial in improving the TSF thickness in CPD patients with a low TSF. |
本系統中英文摘要資訊取自各篇刊載內容。